Sigrid V. Carlsson, MD, PhD, MPH, presented “ChatGPT and AI for Academic Urologists: The Good, the Bad and the Ugly” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Carlsson, Sigrid V. “ChatGPT and AI for Academic Urologists: The Good, the Bad and the Ugly.” August 2024. Accessed Dec 2024. https://grandroundsinurology.com/chatgpt-and-ai-for-academic-urologists-the-good-the-bad-and-the-ugly/
ChatGPT and AI for Academic Urologists: The Good, the Bad and the Ugly – Summary
Sigrid V. Carlsson, MD, PhD, MPH, explores the role of generative AI, particularly large language models (LLMs), in enhancing academic and research activities, while highlighting both the benefits and challenges associated with these technologies. In this 8-minute talk, she focuses on LLMs, such as ChatGPT, Grammarly, and Google Gemini, which produce text and are widely used by researchers to improve grammar, style, and clarity.
The presentation also addresses significant ethical and practical concerns related to AI usage. Dr. Carlsson stresses that AI should not be treated as a substitute for human expertise but as a supplementary tool that requires diligent oversight.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Sigrid V. Carlsson, MD, PhD, MPH, is Director of Clinical Research at Memorial Sloan Kettering Cancer Center’s (MSKCC) Josie Robertson Surgery Center and Assistant Attending Epidemiologist, with dual appointments in MSKCC’s Departments of Surgery (Urology Service) and Epidemiology and Biostatistics. Her line of research focuses on screening and early detection of prostate cancer, including multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging, as recently funded by an NIH/NCI U01 award (PI: Carlsson).
Dr. Carlsson also serves as Associate Professor of Experimental Urology affiliated with the Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, in Sweden, where she is an investigator of two large randomized controlled trials of prostate cancer screening (GOTEBORG-1&2), as recently published in the New England Journal of Medicine (Hugosson J, et al. N Engl J Med 2022). In addition, Dr. Carlsson is Adjunct Senior Lecturer in the Department of Translational Medicine in the Division of Urological Cancers in the Medical Faculty at Lund University, Lund, Sweden.
Dr. Carlsson recently completed a K22 career development award from the NIH/NCI to improve shared decision-making for breast and prostate cancer screening. She serves on the National Comprehensive Cancer Network (NCCN) and is a panel member for the American Urological Association (AUA) guidelines for early detection of prostate cancer. Before pursuing postdoctoral studies in urologic oncology at MSKCC, Dr. Carlsson was a physician in Sweden. She earned her MD and PhD from Gothenburg University in Sweden and earned an MPH from Harvard TH Chan School of Public Health in Boston, Massachusetts.
